Session » (0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I
-
Abstract Number: 0510
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
-
Abstract Number: 0511
Long-term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies
-
Abstract Number: 0512
Factors Associated with Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-year Follow-up of the DESIR Cohort
-
Abstract Number: 0513
Impact of Pregnancy on Sacroiliac Imaging in Women with Axial Spondyloarthritis: Results of the Analysis of the DESIR Cohort
-
Abstract Number: 0514
Difficult-to-treat Axial Spondyloarthritis Is Associated with Psoriasis and Comorbidities: Results from a Nationwide Study
-
Abstract Number: 0515
Dose Adjustment of Tumor Necrosis Factor Inhibitors Does Not Correlated with Radiographic Progression in Patients with Ankylosing Spondylitis
-
Abstract Number: 0516
Drivers of Treatment Intensification in Patients with Axial Spondyloarthritis and High Disease Activity: Results from a Clinical Practice Registry
-
Abstract Number: 0517
Which ASDAS Cut-Off Corresponds Best to Treatment Intensification in Patients with Axial Spondyloarthritis in Daily Practice?
-
Abstract Number: 0518
Tofacitinib Efficacy and Safety in Patients with Ankylosing Spondylitis by Baseline C-Reactive Protein Levels: A Post Hoc Analysis
-
Abstract Number: 0519
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and Its Open-Label Extension
-
Abstract Number: 0520
How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis?
-
Abstract Number: 0521
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
-
Abstract Number: 0523
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
-
Abstract Number: 0524
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
-
Abstract Number: 0526
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
-
Abstract Number: 0528
Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis
-
Abstract Number: 0529
Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)
-
Abstract Number: 0530
Impact of Upadacitinib on Wearable Device-Measured Physical Activity in Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Trial
-
Abstract Number: 0531
Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis
-
Abstract Number: 0532
Factors Associated with Cause-specific Discontinuation of Long-term Anti-tumor Necrosis Factor Agent Use in Patients with Ankylosing Spondylitis
-
Abstract Number: 0533
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?
-
Abstract Number: 0534
Tapering Tofacitinib for Axial Spondyloarthritis in Remission or Low-disease Activity State
-
Abstract Number: 0535
Pharmacologic Treatment of Ankylosing Spondylitis in a Large Urban Medical Center: Effects of Socioeconomic Status, Race/Ethnicity and Sex
-
Abstract Number: 0536
Asynchronous Tele Consultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy: Patients Perspective
-
Abstract Number: 0537
Asynchronous Teleconsultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy as a More Sustainable Model Than Face-to-face Classical Consultation
-
Abstract Number: 0538
The Challenge of Identifying Difficult-To-Treat Axial Spondyloarthritis in Clinical Practice: Results from La Paz-SpA Cohort
-
Abstract Number: 0539
Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis
-
Abstract Number: 0540
The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study